Combine COTELLIC with Zelboraf to achieve
powerful efficacy in patients with BRAF V600(+) metastatic melanoma1
Indication and dosing
Indication
COTELLIC® (cobimetinib) is indicated for use in combination with ZELBORAF® (vemurafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation